Hospital
The Mercy Hospital INC
The Mercy Hospital INC was paid $98.92M by Medicaid between Jan 2018 and Dec 2024, across 343 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoTHE MERCY HOSPITAL INC
SPRINGFIELD, MA 01104
SPRINGFIELD, MA 01104
33aNPI1043204316assigned 09/01/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$98.92M
24GClaims2,014,914
24DCodes billed343
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#14 of 66
Median peer was paid$29.11M
This provider vs. median3.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HARRIS, JAMES controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 332,903 | $17.66M | |
| 2019 | 347,541 | $14.91M | |
| 2020 | 287,184 | $13.10M | |
| 2021 | 340,086 | $15.14M | |
| 2022 | 301,473 | $15.04M | |
| 2023 | 241,153 | $13.12M | |
| 2024incomplete | 164,574 | $9.95M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 90,209 | 84,385 | $13.57M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 78,596 | 72,654 | $12.94M |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 30,784 | 27,872 | $10.89M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.3% | 61,046 | 57,717 | $9.25M |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 2.9% | 2,708 | 2,688 | $2.84M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.7% | 31,467 | 10,681 | $2.64M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.6% | 16,259 | 15,678 | $2.53M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.2% | 3,579 | 3,518 | $2.21M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 16,853 | 16,051 | $2.12M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 11,540 | 11,172 | $1.71M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.5% | 1,776 | 1,749 | $1.53M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 14,125 | 11,719 | $1.48M |
331 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 9,136 | $1.40M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 7,732 | $1.35M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 8,693 | $1.14M |
| 93971 | 1.1% | 5,915 | $1.05M | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,203 | $978K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,026 | $966K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12,628 | $916K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 9,251 | $878K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 20,538 | $844K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,327 | $776K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 12,567 | $768K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 21,108 | $755K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 6,863 | $743K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 11,827 | $728K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,983 | $714K |
| 93970 | <1% | 3,006 | $645K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 126,781 | $604K |
| 59025 | Fetal non-stress test | <1% | 2,317 | $594K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,592 | $517K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 14,698 | $510K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 48,126 | $479K |
| 97035 | <1% | 5,675 | $465K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 52 | $418K |
| 97597 | <1% | 5,769 | $416K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,870 | $411K |
| J2350 | Injection, ocrelizumab, 1 mg | <1% | 60 | $388K |
| 97162 | <1% | 6,438 | $386K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,731 | $381K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 11,215 | $371K |
| 96415 | <1% | 1,595 | $347K | |
| 80053 | Comprehensive metabolic panel | <1% | 65,838 | $345K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,448 | $345K |
| G0378 | Hospital observation service, per hour | <1% | 15,273 | $344K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,218 | $330K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,064 | $328K |
| S9485 | Crisis intervention mental health services, per diem | <1% | 693 | $319K |
| 93017 | <1% | 3,686 | $313K | |
| 47562 | <1% | 98 | $308K | |
| 43235 | <1% | 405 | $298K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 42,598 | $290K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12,999 | $276K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,716 | $257K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 39,761 | $256K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 64,076 | $250K |
| 83690 | <1% | 56,045 | $246K | |
| 12001 | <1% | 1,050 | $234K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,832 | $206K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,597 | $206K |
| 76642 | <1% | 1,919 | $205K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,461 | $196K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 61,881 | $181K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,588 | $180K |
| 93225 | <1% | 3,253 | $178K | |
| 71250 | <1% | 2,658 | $173K | |
| 95886 | <1% | 618 | $170K | |
| 76770 | <1% | 1,159 | $169K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,198 | $166K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,118 | $163K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 30,859 | $162K |
| 52356 | <1% | 45 | $151K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 589 | $145K |
| 81001 | <1% | 69,036 | $140K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 1,277 | $140K |
| 77065 | Tomosynthesis, mammo | <1% | 1,709 | $131K |
| J2323 | Injection, natalizumab, 1 mg | <1% | 26 | $129K |
| 10061 | <1% | 661 | $128K | |
| 83735 | <1% | 32,568 | $124K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 301 | $123K |
| 81025 | <1% | 22,810 | $123K | |
| 93351 | <1% | 568 | $122K | |
| ATP14 | <1% | 12,162 | $119K | |
| 96367 | <1% | 1,353 | $111K | |
| 83880 | <1% | 6,415 | $99K | |
| 87077 | <1% | 10,767 | $96K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 9,879 | $96K |
| 85730 | <1% | 27,733 | $95K | |
| 83721 | <1% | 16,324 | $94K | |
| 97163 | <1% | 1,039 | $92K | |
| 0240U | <1% | 958 | $92K | |
| 71271 | <1% | 2,620 | $91K | |
| 73564 | <1% | 6,557 | $90K | |
| 87040 | <1% | 9,400 | $86K | |
| 87590 | <1% | 4,975 | $85K | |
| 84484 | <1% | 14,538 | $83K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,146 | $83K |
| 85610 | <1% | 31,984 | $82K | |
| 93226 | <1% | 3,236 | $80K | |
| 90715 | <1% | 3,563 | $80K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,119 | $79K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 24,226 | $78K |
| 87490 | <1% | 4,875 | $78K | |
| 88342 | <1% | 1,585 | $77K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 779 | $74K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,621 | $73K |
| 83605 | <1% | 10,860 | $70K | |
| 97166 | <1% | 620 | $68K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 445 | $66K |
| 76536 | <1% | 435 | $64K | |
| ATP08 | <1% | 8,061 | $62K | |
| 73030 | <1% | 5,149 | $60K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 40,444 | $60K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 29,210 | $57K |
| 73630 | <1% | 5,465 | $56K | |
| 74246 | <1% | 283 | $55K | |
| 74018 | <1% | 3,119 | $54K | |
| 97033 | <1% | 561 | $54K | |
| 77412 | <1% | 142 | $53K | |
| 72110 | <1% | 876 | $53K | |
| 36430 | <1% | 256 | $52K | |
| 87147 | <1% | 4,982 | $51K | |
| 88307 | <1% | 529 | $50K | |
| 73130 | <1% | 4,955 | $50K | |
| 97161 | <1% | 778 | $50K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,292 | $48K |
| 12002 | <1% | 208 | $48K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 682 | $47K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 335 | $46K |
| 73610 | <1% | 5,048 | $46K | |
| 87186 | <1% | 8,260 | $44K | |
| 84702 | <1% | 3,518 | $43K | |
| 70486 | <1% | 1,052 | $43K | |
| 72050 | <1% | 1,147 | $42K | |
| 87088 | <1% | 8,415 | $41K | |
| 93880 | <1% | 523 | $40K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 11,058 | $40K |
| 77080 | <1% | 770 | $39K | |
| 87070 | <1% | 6,204 | $38K | |
| 36591 | <1% | 5,749 | $38K | |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | <1% | 2,770 | $38K |
| 85379 | <1% | 5,962 | $37K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,622 | $37K |
| 87430 | <1% | 3,251 | $37K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 883 | $36K |
| 87808 | <1% | 3,525 | $36K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 15,282 | $35K |
| 97165 | <1% | 337 | $34K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 184 | $34K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 7,988 | $34K |
| 93925 | <1% | 358 | $33K | |
| 87634 | <1% | 660 | $32K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,203 | $32K |
| 80076 | <1% | 10,182 | $31K | |
| 72100 | <1% | 4,671 | $30K | |
| 0002A | <1% | 1,090 | $30K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 20,996 | $30K |
| 12011 | <1% | 123 | $30K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,801 | $29K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15,929 | $29K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 95 | $29K |
| 73110 | <1% | 2,503 | $28K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 14,681 | $28K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 18,222 | $28K |
| 92567 | <1% | 441 | $27K | |
| 70491 | <1% | 168 | $27K | |
| 74220 | <1% | 342 | $26K | |
| 73502 | <1% | 2,186 | $25K | |
| 29125 | <1% | 159 | $25K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 49 | $24K |
| 0001A | <1% | 1,068 | $24K | |
| 96523 | <1% | 342 | $24K | |
| 92523 | <1% | 167 | $23K | |
| 94060 | <1% | 203 | $23K | |
| J2704 | Injection, propofol, 10 mg | <1% | 29,063 | $23K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,121 | $23K |
| 77336 | <1% | 181 | $22K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 9,058 | $22K |
| 85027 | <1% | 6,001 | $21K | |
| 70496 | <1% | 138 | $21K | |
| 76870 | <1% | 207 | $21K | |
| 97010 | <1% | 212 | $20K | |
| 93325 | <1% | 114 | $20K | |
| 10060 | <1% | 105 | $20K | |
| 84703 | <1% | 3,034 | $18K | |
| 77066 | Tomosynthesis, mammo | <1% | 612 | $17K |
| ATP15 | <1% | 1,732 | $17K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 104 | $16K |
| 77062 | <1% | 138 | $16K | |
| 86900 | <1% | 6,783 | $16K | |
| 86850 | <1% | 3,454 | $15K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 541 | $15K |
| 97167 | <1% | 127 | $15K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 104 | $15K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,319 | $14K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 69 | $14K |
| 87210 | <1% | 3,691 | $14K | |
| 97032 | <1% | 171 | $14K | |
| 73080 | <1% | 1,263 | $13K | |
| 73140 | <1% | 1,270 | $13K | |
| 86140 | <1% | 4,022 | $12K | |
| 84439 | <1% | 2,121 | $12K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 6,088 | $12K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,574 | $11K |
| 93922 | <1% | 287 | $11K | |
| 82010 | <1% | 2,079 | $11K | |
| 87486 | <1% | 503 | $11K | |
| 87581 | <1% | 503 | $11K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,444 | $10K |
| 95957 | <1% | 82 | $10K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 5,139 | $10K |
| 94727 | <1% | 174 | $9K | |
| 92587 | <1% | 53 | $9K | |
| 84146 | <1% | 648 | $8K | |
| 85651 | <1% | 3,503 | $8K | |
| 72070 | <1% | 274 | $7K | |
| 82140 | <1% | 1,002 | $7K | |
| 95885 | <1% | 27 | $7K | |
| 87205 | <1% | 2,671 | $7K | |
| 88304 | <1% | 2,388 | $6K | |
| 82550 | <1% | 3,035 | $6K | |
| 97116 | <1% | 129 | $6K | |
| V5266 | Battery for use in hearing device | <1% | 348 | $6K |
| 92552 | <1% | 56 | $6K | |
| 71101 | <1% | 967 | $6K | |
| 94729 | <1% | 187 | $6K | |
| 80061 | Lipid panel | <1% | 1,259 | $6K |
| 82805 | <1% | 137 | $6K | |
| 84100 | <1% | 3,037 | $6K | |
| 82728 | <1% | 717 | $5K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 6,164 | $5K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,699 | $5K |
| 96376 | <1% | 7,148 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,048 | $5K |
| 84481 | <1% | 377 | $4K | |
| 80051 | <1% | 2,230 | $4K | |
| 97012 | <1% | 49 | $4K | |
| 70490 | <1% | 142 | $4K | |
| 76801 | <1% | 414 | $4K | |
| 99205 | Prolong outpt/office vis | <1% | 27 | $4K |
| 82565 | <1% | 2,426 | $4K | |
| 76882 | <1% | 26 | $4K | |
| 0012A | <1% | 99 | $4K | |
| 74420 | <1% | 141 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,151 | $4K |
| 0011A | <1% | 124 | $3K | |
| 92579 | <1% | 192 | $3K | |
| 76942 | <1% | 25 | $3K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 56 | $3K |
| 84520 | <1% | 2,113 | $3K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 24 | $2K |
| 72040 | <1% | 56 | $2K | |
| 73090 | <1% | 214 | $2K | |
| 97164 | <1% | 26 | $2K | |
| 86618 | <1% | 173 | $2K | |
| 95910 | <1% | 14 | $2K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 63 | $2K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 71 | $2K |
| 73590 | <1% | 402 | $2K | |
| 96417 | <1% | 284 | $2K | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 38 | $2K |
| 90686 | <1% | 104 | $2K | |
| 86920 | <1% | 59 | $2K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 39 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,634 | $2K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 12 | $2K |
| G0238 | Therapeutic procedures to improve respiratory function, other than described by g0237, one on one, face to face, per 15 minutes (includes monitoring) | <1% | 1,325 | $2K |
| 82607 | <1% | 185 | $1K | |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 12 | $1K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 12 | $1K |
| 83615 | <1% | 589 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 61 | $1K |
| 88173 | <1% | 12 | $868.00 | |
| ATP09 | <1% | 87 | $712.88 | |
| 86780 | <1% | 53 | $686.67 | |
| 80050 | General health panel | <1% | 37 | $626.78 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 563 | $623.67 |
| 73660 | <1% | 53 | $601.15 | |
| 86803 | <1% | 53 | $573.21 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 44 | $550.94 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 233 | $509.45 |
| 93976 | <1% | 16 | $486.04 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 37 | $455.94 |
| 96411 | <1% | 85 | $356.50 | |
| 84460 | <1% | 149 | $350.63 | |
| 84450 | <1% | 147 | $343.35 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 161 | $303.96 |
| 87015 | <1% | 52 | $279.71 | |
| 82746 | <1% | 42 | $262.04 | |
| 74022 | <1% | 29 | $259.35 | |
| 84550 | <1% | 88 | $176.83 | |
| 80164 | <1% | 40 | $172.90 | |
| 82040 | <1% | 81 | $171.31 | |
| 86708 | <1% | 15 | $158.20 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,118 | $154.26 |
| 88311 | <1% | 84 | $142.92 | |
| J1815 | Injection, insulin, per 5 units | <1% | 581 | $132.42 |
| 82247 | <1% | 51 | $103.34 | |
| 81003 | <1% | 75 | $95.04 | |
| 86901 | <1% | 41 | $92.40 | |
| 86308 | <1% | 12 | $64.08 | |
| 87184 | <1% | 13 | $62.90 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 931 | $58.99 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 108 | $54.04 |
| 84075 | <1% | 27 | $53.59 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 154 | $42.38 |
| Q3014 | Telehealth originating site facility fee | <1% | 159 | $40.09 |
| 83540 | <1% | 12 | $35.40 | |
| 72020 | <1% | 28 | $14.87 | |
| ATP03 | <1% | 30 | $13.70 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 94 | $13.12 |
| A9270 | Non-covered item or service | <1% | 2,883 | $1.50 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 49 | $0.46 |
| 99152 | 0% | 385 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 800 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 795 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 71 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 319 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 190 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 78 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 17 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 16 | $0.00 |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | 0% | 27 | $0.00 |
| 94760 | 0% | 3,627 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 516 | $0.00 |
| C1769 | Guide wire | 0% | 402 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 876 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 765 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,266 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 523 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 234 | $0.00 |
| 88300 | 0% | 16 | $0.00 | |
| 96368 | 0% | 35 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 14 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 20 | $0.00 |
| 97014 | 0% | 31 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 16 | $0.00 |
| 73060 | 0% | 25 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 13 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 18 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 35 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 26 | $0.00 |
| 92556 | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRIS, JAMES (REGIONAL DIRECTOR OF REIMBURSEMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.